Ovid Therapeutics (NASDAQ: OVID) is one of 289 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it compare to its competitors? We will compare Ovid Therapeutics to similar companies based on the strength of its profitability, earnings, risk, valuation, institutional ownership, analyst recommendations and dividends.
Earnings & Valuation
This table compares Ovid Therapeutics and its competitors gross revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Ovid Therapeutics||N/A||-$22.41 million||-2.46|
|Ovid Therapeutics Competitors||$290.27 million||$35.99 million||54.87|
This is a summary of current ratings and recommmendations for Ovid Therapeutics and its competitors, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Ovid Therapeutics Competitors||1134||3421||11923||240||2.67|
Ovid Therapeutics currently has a consensus target price of $23.50, suggesting a potential upside of 146.85%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 39.40%. Given Ovid Therapeutics’ stronger consensus rating and higher probable upside, equities research analysts plainly believe Ovid Therapeutics is more favorable than its competitors.
Insider and Institutional Ownership
29.4% of Ovid Therapeutics shares are held by institutional investors. Comparatively, 49.8% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 16.8% of shares of all “Bio Therapeutic Drugs” companies are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
This table compares Ovid Therapeutics and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Ovid Therapeutics Competitors||-6,417.56%||-86.59%||-37.07%|
Ovid Therapeutics competitors beat Ovid Therapeutics on 7 of the 12 factors compared.
About Ovid Therapeutics
Ovid Therapeutics Inc. (Ovid) is a biopharmaceutical company. The Company is engaged in developing medicines for patients and families living with rare neurological disorders. Its lead drug candidate is OV101. The Company’s second lead drug candidate is OV935. OV101 (gaboxadol) is a delta-selective GABAA receptor agonist. Ovid is developing OV101 for use in both Angelman syndrome and Fragile X syndrome to potentially restore tonic inhibition and relieve several of the symptoms of these disorders. Ovid has initiated the Phase II STARS trial of OV101 in adults with Angelman syndrome and a Phase I trial in adolescents with Angelman syndrome or Fragile X syndrome. Ovid is also developing OV935 in collaboration with Takeda Pharmaceutical Company Limited for the treatment of rare epileptic encephalopathies.
What are top analysts saying about Ovid Therapeutics? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Ovid Therapeutics and related companies.